- The validation confirms that the submission is sufficiently complete to begin the formal review process for the non-invasive, once-daily epicutaneous patch to treat peanut allergies in children ages 4 to 11 years.
Catalyst
Slingshot members are tracking this event:
DBV Technologies (DBVT) Announces Marketing Authorization Application Approval for Viaskin Peanut by European Medicines Agency
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| DBVT |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 02, 2020
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Viaskin, Viaskin Peanut
